Information Provided By: 
Fly News Breaks for February 7, 2019
SPPI
Feb 7, 2019 | 07:30 EDT
Cantor Fitzgerald analyst Alethia Young started Spectrum Pharmaceuticals with an Overweight rating and $19 price target. The analyst has confidence that poziotinib can show a differentiated response in the pivotal Phase 2 study and believes the value for Rolontis is being underappreciated. This "provides some floor to the valuation," Young tells investors in a research note. With no approved drugs for exon 20, the analyst thinks the efficacy bar is relatively low.
News For SPPI From the Last 2 Days
There are no results for your query SPPI
